SOPH · Nasdaq · ·
Next earnings: November 3, 2026
$8.29-2.5%Sep 29 close
Sophia Genetics SA is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $21.7M | $17.7M | +22.30% |
| Free Cash Flow | -$16M | -$12.3M | -30.14% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sophia Genetics SA has no earnings call transcript available.
“We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM™, an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Sophia Genetics SA filed on August 4, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.